1. Home
  2. OCSL vs ZYME Comparison

OCSL vs ZYME Comparison

Compare OCSL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCSL
  • ZYME
  • Stock Information
  • Founded
  • OCSL 2007
  • ZYME 2003
  • Country
  • OCSL United States
  • ZYME United States
  • Employees
  • OCSL N/A
  • ZYME N/A
  • Industry
  • OCSL Finance: Consumer Services
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • OCSL Finance
  • ZYME Health Care
  • Exchange
  • OCSL Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • OCSL 1.1B
  • ZYME 1.2B
  • IPO Year
  • OCSL 2008
  • ZYME 2017
  • Fundamental
  • Price
  • OCSL $13.87
  • ZYME $18.83
  • Analyst Decision
  • OCSL Hold
  • ZYME Strong Buy
  • Analyst Count
  • OCSL 6
  • ZYME 9
  • Target Price
  • OCSL $15.20
  • ZYME $22.88
  • AVG Volume (30 Days)
  • OCSL 891.5K
  • ZYME 865.0K
  • Earning Date
  • OCSL 11-18-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • OCSL 11.56%
  • ZYME N/A
  • EPS Growth
  • OCSL N/A
  • ZYME N/A
  • EPS
  • OCSL 0.55
  • ZYME N/A
  • Revenue
  • OCSL $334,099,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • OCSL N/A
  • ZYME $99.52
  • Revenue Next Year
  • OCSL N/A
  • ZYME N/A
  • P/E Ratio
  • OCSL $25.32
  • ZYME N/A
  • Revenue Growth
  • OCSL N/A
  • ZYME 95.94
  • 52 Week Low
  • OCSL $12.44
  • ZYME $9.03
  • 52 Week High
  • OCSL $16.53
  • ZYME $19.98
  • Technical
  • Relative Strength Index (RSI)
  • OCSL 57.67
  • ZYME 63.19
  • Support Level
  • OCSL $13.71
  • ZYME $17.27
  • Resistance Level
  • OCSL $14.05
  • ZYME $19.98
  • Average True Range (ATR)
  • OCSL 0.27
  • ZYME 0.73
  • MACD
  • OCSL 0.06
  • ZYME 0.01
  • Stochastic Oscillator
  • OCSL 71.78
  • ZYME 58.30

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: